Additionally, PD-1 inhibitors and tyrosine kinase inhibitors have been found in several clinical studies to have effective anti-tumor effects when used in the treatment of advanced HCC (18, 19). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.